Skip to content

A Comparative Study To Evaluate The Effect Of Two Ayurvedic Therapies In Management Of Parkinsons Disease

Comparative Clinical Evaluation Of Kala Basti With And Without Shirobasti In Kampavata (Parkinsons Disease) - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/07/113477
Enrollment
60
Registered
2026-07-06
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G20- Parkinsons disease

Interventions

None listed

Sponsors

Patanjali Bhartiya Ayurvigyan Evam Anusandhan Sansthan Haridwar Uttarakhand
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients with age group of 40 to 70 years of both genders. 2) Patients of any socio-economic status,religion,occupation. 3) Patients with clinical features of Kampvata. 4) Patients fit for Basti Karma and Shirobasti.

Exclusion criteria

Exclusion criteria: 1) Patients between less than 40 years old and more than 70 years old. 2) Patients with history of Diabetes Mellitus, Cardiac Anomalies, Tuberculosis, Hypertension or Thyroid dysfunction. 3) Patients with severe complications. 4) Patients having any other disease causing tremors and bradykinesia(like Wilson s Disease,Huntington s Disease). 5) Pregnant & lactating women. 6) Patients unfit for Basti Karma and Shirobasti.

Design outcomes

Primary

MeasureTime frame
Subjective Parameters Kampa Gatisang Vakvikriti StambhTimepoint: 9, 30 days

Secondary

MeasureTime frame
Objective Parameters Marie Sign Buttonning Time Hand Grip Power Rapid Alternating Movements Pin Picking Test Chest Expansion Foot PressureTimepoint: 9,30 days

Countries

India

Contacts

Public ContactDr Ayushi Kasyap

Patnjali Bhartiya Ayurvigyan Evam Anusandhan Sansthan

atulagrawal98@gmail.com7579126092

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026